Introduction {#s1}
============

*Staphylococcus aureus* bacteraemia (SAB) is a serious infection associated with significant complications, including infective endocarditis (IE) and other metastatic deep tissue infections as well as high rates of mortality.^[@DKP051C1]--[@DKP051C5]^ Rates of infection caused by methicillin-resistant *S*. *aureus* (MRSA) are increasing,^[@DKP051C6]^ and MRSA infections are associated with a greater risk of complications than are those due to methicillin-susceptible isolates. The mortality risk is approximately two to three times greater in patients with MRSA bacteraemia than in those with methicillin-susceptible *S*. *aureus* (MSSA) bacteraemia.^[@DKP051C3],[@DKP051C4]^

Patients with SAB/IE are likely to receive intravenous (iv) antimicrobial therapy for up to 4--6 weeks. An increasing focus on hospital costs and pressure to free up expensive hospital beds have motivated clinicians to seek alternative therapeutic approaches, including community-based outpatient parenteral antimicrobial therapy (CoPAT). Numerous reports describing the use of CoPAT in a broad cross-section of patient populations support the notion that selected patients with SAB/IE---in particular, those who have stabilized in the hospital---may be candidates for the completion of therapy in a community setting.^[@DKP051C7]--[@DKP051C10]^ Typical community-based settings involve home treatment as well as treatment at nursing facilities, assisted-living facilities and rehabilitation centres. Although most studies of outpatient parenteral antimicrobial therapy (OPAT) involve registries, or are otherwise retrospective in nature, the available data show that cure rates are generally \>90% for bacterial infections of all kinds.^[@DKP051C8],[@DKP051C9],[@DKP051C11]^

While OPAT studies are plentiful, there is a paucity of data from controlled clinical trials. The recently completed prospective, randomized trial comparing daptomycin with standard therapy for SAB/IE captured detailed data on patients treated both inside and outside the hospital setting. In this study, standard therapy, against which daptomycin treatment was compared, consisted of a semi-synthetic penicillin or vancomycin, each with 4 days of initial low-dose gentamicin \[1 mg/kg every 8 h, adjusted as appropriate for creatinine clearance (CL~CR~)\].^[@DKP051C12]^

The unique database generated during the course of the randomized trial provides an opportunity to assess the impact of treatment setting on patients being treated for a serious infection. Therefore, we conducted a further analysis of the data to examine the clinical course of patients who completed their antibiotic therapy in the hospital compared with those who received some portion in the CoPAT setting.

Methods {#s2}
=======

Using data from the open-label, randomized, controlled trial of daptomycin versus standard therapy (semi-synthetic penicillin or vancomycin, each with initial low-dose gentamicin) for SAB/IE,^[@DKP051C12]^ the characteristics and outcomes of patients were evaluated based on treatment setting during administration of iv antimicrobial therapy. The randomized clinical trial is registered with ClinicalTrials.gov (NCT00093067). The protocol, approved by the Institutional Review Board at each site, was consistent with the principles of the Declaration of Helsinki. All patients or their authorized representatives provided written informed consent. While the trial was conducted in several countries, this analysis was limited to patients treated in the USA because of differences in outpatient antimicrobial treatment approaches outside of the USA. Data included patient location during treatment with the study drug, including any changes in level of care (Table [1](#DKP051TB1){ref-type="table"}), and treatment outcome. Comparisons were made to elucidate the impact of changes in level of care.

###### 

Demographics, diagnosis and treatment characteristics by treatment location

  Characteristic                        CoPAT (*n* = 103)   IPAT (*n* = 97)   *P*^a^
  ------------------------------------- ------------------- ----------------- ------------
  Study drug                                                                  
   daptomycin                           50 (48.5%)^b^       50 (51.5%)        0.687^c^
   vancomycin^d^                        30 (29.1%)          23 (23.7%)        
   SSP^d^                               23 (22.3%)          24 (24.7%)        
  Age (years)                                                                 
   median                               50.0                54.0              0.028^e^
   range                                21--90              24--91            
  Male                                  60 (58.3%)          59 (60.8%)        0.774
  Race                                                                        
   white                                66 (64.1%)          55 (56.7%)        0.070^c^
   black                                30 (29.1%)          25 (25.8%)        
   other                                7 (6.8%)            17 (17.5%)        
  Weight (kg)                                                                 
   median                               81.7                78.2              0.493^e^
   range                                49.9--129.0         53.5--131.4       
  MRSA                                  37 (35.9%)          39 (40.6%)^f^     0.560
  CL~CR~ (mL/min)                                                             
   median                               92.1                86.0              0.064^e^
   range                                29.4--277.0         17.9--200.8       
  CL~CR~ \<50 mL/min                    12 (11.7%)          12 (12.4%)        \>0.999
  Evidence of endocardial involvement   9 (8.7%)            18 (18.6%)        0.061
  Injection drug use                    26 (25.2%)          22 (22.7%)        0.741
  Pre-existing valvular heart disease   8 (7.8%)            15 (15.5%)        0.120
  Fever on day 4                        10 (9.7%)           18 (18.8%)^g^     0.101
  Completed treatment                   93 (90.3%)          44 (45.4%)        \<0.001
  Duration of treatment (days)                                                
   mean (SD)                            25.4 (12.34)        13.5 (9.49)       \<0.001^h^
   range                                9--74               1--43             
  Days inpatient during treatment                                             
   mean (SD)                            10.5 (7.27)         13.5 (9.49)       0.014^h^
   range                                2--38               1--43             
  Days outpatient during treatment                                            
   mean (SD)                            14.9 (10.08)        0                 NA
   range                                1--49               ---               
  Experienced ≥1 SAE                    48 (46.6%)          52 (53.6%)        0.396

CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting; SSP, semi-synthetic penicillin; MRSA, methicillin-resistant *S. aureus*; NA, not applicable; SAE, serious adverse event.

^a^Fisher\'s exact test, unless otherwise specified.

^b^No. (%), unless otherwise specified.

^c^Overall Fisher\'s exact test for characteristic.

^d^With or without concomitant gentamicin.

^e^Wilcoxon\'s rank sum test.

^f^*n* = 96 for MRSA.

^g^*n* = 96 for fever (inpatient): fever on day 4 was possible but not definitive on day 4 for six patients in the inpatient group who were considered to have not had a fever.

^h^*t*-test.

To be enrolled in the SAB/IE study, patients had to be at least 18 years of age and have had at least one blood culture growing *S*. *aureus* within 2 days before the first administration of the study drug. Exclusion criteria included CL~CR~ \<30 mL/min and the presence of known osteomyelitis, polymicrobial bacteraemia or pneumonia. Patients were evaluated at the end of therapy and 42 days after the end of therapy to determine treatment success and rule out relapse.^[@DKP051C12]^ Patients with persisting/relapsing *S*. *aureus* infection, death or clinical failure within 6 weeks of the end of therapy were considered clinical failures. This analysis did not consider administrative reasons for failure that were included in the primary efficacy analysis of the original study, such as discontinuation caused by an adverse event, administration of a potentially effective non-study drug and no blood culture drawn at test-of-cure visit.^[@DKP051C12]^

The protocol allowed completion of therapy in community care settings. The decision to pursue CoPAT was based on the investigators\' assessment of patients\' clinical stability, including the absence of surgical indications.^[@DKP051C13]^ Psychosocial characteristics and the availability of appropriate community care services were also considered. Patients receiving their full course of antimicrobial therapy in the hospital setting, categorized as inpatient antimicrobial therapy (IPAT), were compared with those receiving some portion of antimicrobial therapy outside of the hospital, categorized as CoPAT. For the purposes of this analysis, IPAT was defined as all care in one or more of the following locations: (i) hospital intensive care unit; (ii) hospital step-down unit; and (iii) general hospital ward. CoPAT was defined as initial inpatient treatment followed by care in one or more of the following locations: (i) skilled nursing facility; (ii) assisted-living setting, nursing home or rehabilitation centre; (iii) at-home treatment with assistance; and (iv) at-home treatment without assistance. Escalation of care was defined as any transfer to a location providing a higher level of care, as ordered above, for example, from ward to intensive care unit or home to ward.

iv access for CoPAT was selected by individual physicians and established prior to hospital discharge. Antibiotics were pre-mixed by an infusion pharmacy and delivered every 48 h. Vancomycin was administered as an infusion over at least 1 h; daptomycin and semi-synthetic penicillin doses were infused over 30 min. Vancomycin and daptomycin infusions were administered by nurses in all settings. Patients receiving semi-synthetic penicillins at home were treated via an ambulatory infusion pump programmed by home care nurses to deliver doses at 4 h intervals around the clock. Nurses monitored patients\' overall status and vital signs daily during CoPAT; physicians were notified of changes in conditions. Except for end of therapy and test-of-cure visits, physician office follow-up was not standardized. Per study protocol, blood chemistries, complete blood counts and creatine phosphokinase levels were obtained weekly in all care settings.

Patient characteristics and outcomes were analysed using Fisher\'s exact test for categorical data and a two-sample *t*-test or the Wilcoxon rank sum test for continuous data. All tests were two-sided. All analyses were performed using SAS® software, Version 9.1.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

Two hundred US patients were included in this analysis, with 103 (51.5%) receiving part of their treatment outside of the hospital setting (CoPAT). The majority of CoPAT patients (69/103, 67.0%) were discharged home without assistance and two others (1.9%) went home with assistance. Nineteen of the 103 CoPAT patients (18.4%) were discharged to a skilled nursing facility, while 13/103 (12.6%) were treated in an assisted-living setting, nursing home or rehabilitation centre. The study database did not systematically record the types of venous access devices used to deliver CoPAT. In general, peripherally inserted central catheters were the preferred means of securing venous access.

Compared with patients who received all care in the hospital, CoPAT patients were younger (median age 50 versus 54 years, *P* = 0.028) and tended to have fewer cases of endocardial involvement (8.7% versus 18.6%; *P* = 0.061) as well as less pre-existing valvular heart disease (7.8% versus 15.5%, *P* = 0.120). The two groups had a similar distribution of diagnoses (Figure [1](#DKP051F1){ref-type="fig"}) and a similar distribution of study medications. Baseline demographic, diagnostic and treatment characteristics are shown in Table [1](#DKP051TB1){ref-type="table"}.

![Final diagnosis by CoPAT or IPAT treatment. CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting; uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis; LIE, left-sided infective endocarditis.](dkp05101){#DKP051F1}

Other differences between the treatment groups included a trend towards higher baseline CL~CR~ in the CoPAT patients (median 92.1 versus 86.0 mL/min, *P* = 0.064) and a trend towards a lower percentage of CoPAT patients with fever at day 4 of treatment (9.7% versus 18.8%, *P* = 0.101). Among CoPAT patients, baseline characteristics were similar for those receiving either daptomycin or comparator treatment (Table [2](#DKP051TB2){ref-type="table"}).

###### 

Demographic, diagnosis and treatment characteristics by treatment group among CoPAT patients

  Characteristic                        Daptomycin (*n* = 50)   Comparator^a^ (*n* = 53)
  ------------------------------------- ----------------------- --------------------------
  Age (years)                                                   
   median                               46.5                    52.0
   range                                21--81                  25--90
  Gender                                                        
   male                                 31 (62.0%)^b^           29 (54.7%)
  Race                                                          
   white                                26 (52.0%)              40 (75.5%)
   black                                19 (38.0%)              11 (20.8%)
   other                                5 (10.0%)               2 (3.8%)
  Weight (kg)                                                   
   median                               82.1                    80.0
   range                                55.0--129.0             49.9--124.8
  MRSA                                  18 (36.0%)              19 (35.8%)
  CL~CR~ (mL/min)                                               
   median                               108.1                   86.4
   range                                29.4--246.9             31.0--277.0
  CL~CR~ \<50 mL/min                    4 (8.0%)                8 (15.1%)
  Evidence of endocardial involvement   4 (8.0%)                5 (9.4%)
  Injection drug use                    14 (28.0%)              12 (22.6%)
  Pre-existing valvular heart disease   3 (6.0%)                5 (9.4%)
  Fever on day 4                        3 (6.0%)                7 (13.2%)
  Completed treatment                   46 (92.0%)              47 (88.7%)
  Duration of treatment (days)                                  
   mean (SD)                            25.9 (13.31)            25.0 (11.46)
   range                                11--74                  9--57
  Days inpatient during treatment                               
   mean (SD)                            10.7 (7.06)             10.3 (7.52)
   range                                5--38                   2--35
  Days outpatient during treatment                              
   mean (SD)                            15.2 (10.08)            14.7 (10.18)
   range                                2--46                   1--49
  Final diagnosis                                               
   uBAC                                 10 (20.0%)              17 (32.1%)
   cBAC                                 27 (54.0%)              24 (45.3%)
   RIE                                  11 (22.0%)              8 (15.1%)
   LIE                                  2 (4.0%)                4 (7.5%)
  Experienced ≥1 SAE                    23 (46.0%)              25 (47.2%)

CoPAT, outpatient parenteral antimicrobial therapy in the community setting; MRSA, methicillin-resistant *S. aureus*; uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis; LIE, left-sided infective endocarditis; SAE, serious adverse event.

^a^Comparator treatment was semi-synthetic penicillin/gentamicin or vancomycin/gentamicin.

^b^No. (%), unless otherwise specified.

Patient outcomes {#s3b}
----------------

Among CoPAT patients, clinical success rates were similar regardless of study medication, with 45/50 (90.0%) daptomycin patients and 44/53 (83.0%) comparator patients experiencing clinical success. For IPAT patients, clinical success was observed in 26/50 (52.0%) daptomycin patients and 28/47 (59.6%) comparator patients. Thus, it is justified to combine the treatment groups for analysis of outcomes.

CoPAT patients received longer courses of study antibiotics with a mean of 25.4 days (range 9--74 days) compared with 13.5 days (range 1--43) in the IPAT group (*P* \< 0.001), and a higher proportion of CoPAT patients completed therapy as part of the study (90.3% versus 45.4%, *P* \< 0.001). CoPAT patients received a mean of 14.9 days of therapy outside the hospital setting (Table [1](#DKP051TB1){ref-type="table"}). The shorter duration of study treatment for IPAT patients was influenced by early discontinuations: there were 53 (54.6%) versus 10 (9.7%) in the CoPAT group. The most common reason for discontinuation was adverse events, which accounted for 25/53 (47.2%) IPAT and 8/10 (80.0%) CoPAT patient discontinuations. The adverse events responsible for discontinuation, including rash, infection, renal failure and creatine phosphokinase elevation, are listed in Table [3](#DKP051TB3){ref-type="table"}. IPAT patients whose study participation was terminated prior to the end of therapy received subsequent antibiotic therapy as appropriate, but specific information regarding types and duration of additional therapy was not part of the study database.

###### 

Adverse events leading to discontinuation

                                           CoPAT (*n* = 8)^a^   IPAT (*n* = 25)^a^
  ---------------------------------------- -------------------- --------------------
  Anaphylactic reaction                    0                    1
  Skin^b^                                  4                    4
  Red man syndrome                         0                    1
  Diabetic gastroparesis                   1                    0
  Vomiting not otherwise specified         0                    1
  Blood creatine phosphokinase increased   1                    2
  Cardiovascular^c^                        0                    4
  Hypoxia                                  0                    1
  Infection^d^                             0                    3
  Fever                                    0                    2
  Renal failure                            2                    3
  Sepsis                                   0                    2
  Thrombocytopenia                         0                    1

^a^Number of discontinuations due to an adverse event.

^b^Skin includes dermatitis bullous, dermatitis medicamentosa, erythematous rash, vesicular rash and rash not otherwise specified.

^c^Cardiovascular includes cardiac arrest (two patients), cerebrovascular accident and circulatory collapse.

^d^Infection includes osteomyelitis not otherwise specified, staphylococcal pneumonia and staphylococcal bacteraemia.

A higher rate of clinical success at the test-of-cure visit was observed among CoPAT patients (89/103, 86.4%) compared with that among IPAT patients (54/97, 55.7%) (*P* \< 0.001). Four of the 103 CoPAT patients (3.9%) experienced persisting or relapsing *S*. *aureus* infection, compared with 15/97 IPAT patients (15.5%, *P* = 0.007). Fewer deaths occurred in the CoPAT group (4/103, 3.9%) compared with those in the IPAT group (18/97, 18.6%; *P* = 0.001) (Table [4](#DKP051TB4){ref-type="table"}).

###### 

Clinical outcomes for CoPAT patients versus IPAT patients

  Clinical outcome 6 weeks after end of therapy   CoPAT^a^ (*n* = 103)   IPAT (*n* = 97)   *P*^b^
  ----------------------------------------------- ---------------------- ----------------- ---------
  Clinical success                                89 (86.4%)^c^          54 (55.7%)        \<0.001
  Failure                                         10 (9.7%)              26 (26.8%)        
  Non-evaluable                                   4 (3.9%)               17 (17.5%)        
  Death                                           4 (3.9%)               18 (18.6%)        0.001

CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting.

^a^Inpatients who were partly treated outside a hospital.

^b^Fisher\'s exact test.

^c^No. (%).

Escalation of care {#s3c}
------------------

Twice as many CoPAT patients (22/103, 21.4%) were transferred to a higher level of care during their course of treatment compared with those transferred among IPAT patients (10/97, 10.3%), a difference that reached statistical significance (*P* = 0.036) (Table [5](#DKP051TB5){ref-type="table"}). Hospital readmission was required for 18 of the 103 (17.5%) CoPAT patients. As shown in Table [6](#DKP051TB6){ref-type="table"}, the reasons for hospital readmission were diverse. Four patients (22.2% of the readmissions and 3.9% of CoPAT patients) were readmitted for reasons related to their initial infection, including osteomyelitis or relapsed SAB. Problems related to provision of treatment in the post-acute care setting led to the readmission of three patients, two of whom relapsed with iv drug use (IVDU) and one of whom developed *Clostridium difficile* colitis. Other medical conditions leading to readmission included pneumonia in three patients and a myriad of other conditions, including unknown reasons, which were each experienced by a single patient. Of the 18 CoPAT patients readmitted to the hospital during the study, half subsequently returned to treatment in the CoPAT setting.

###### 

Escalation of care and patient location at last dose of study drug

  Characteristic                                                           CoPAT (*n* = 103)   IPAT (*n* = 97)
  ------------------------------------------------------------------------ ------------------- -----------------
  Transferred to higher level of care at any time during treatment         22 (21.4%)^a--c^    10 (10.3%)
  No. times readmitted to hospital to complete treatment with study drug                       
   one                                                                     17 (16.5%)          NA
   two                                                                     1 (1.0%)            NA
  Returned to outpatient care after readmission                            9 (50.0%)^d^        NA
  Reasons readmitted                                                                           
   factors relating to initial infection                                   4 (22.2%)           NA
   other conditions^e^                                                     11 (61.1%)          NA
   issues relating to provision of treatment at home                       3 (16.7%)^f^        NA
  Location for last dose of study drug                                                         
   for patients who completed treatment                                    93 (90.3%)          44 (45.4%)
    in hospital setting                                                    8 (7.8%)^g^         44 (45.4%)
    as an outpatient                                                       85 (82.5%)          0
   for patients who prematurely discontinued treatment                     10 (9.7%)           53 (54.6%)
    in hospital setting                                                    2 (1.9%)^g^         53 (54.6%)
    as an outpatient                                                       8 (7.8%)            0

CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting; NA, not applicable.

^a^No. (%).

^b^*P* = 0.036, Fisher\'s exact test.

^c^One patient had increased level of care within post-acute care but was not readmitted to hospital. Three patients had escalation of inpatient care prior to post-acute care.

^d^Based on the 18 patients who were readmitted to hospital.

^e^Underlying disease or new problems not related to the initial infection. See Table [6](#DKP051TB6){ref-type="table"}.

^f^One patient was readmitted twice for the same problem related to delivery of treatment at home. See Table [6](#DKP051TB6){ref-type="table"}.

^g^Patients readmitted to hospital.

###### 

Patient status and factors related to hospital readmission among CoPAT patients

  Characteristic                                              CoPAT patients (*n* = 103)
  ----------------------------------------------------------- ----------------------------
  No. of post-acute care patients readmitted^a^               18/103 (17.5%)^b^
  Reasons for readmission                                     
  Factors relating to initial infection (*n* = 4)             
   osteomyelitis                                              2/18 (11.1%)
   relapsed *S. aureus* bacteraemia                           1/18 (5.6%)
   embolic stroke                                             1/18 (5.6%)
  Other conditions (*n* = 11)                                 
   pneumonia                                                  3/18 (16.7%)
   urinary tract infection                                    1/18 (5.6%)
   fever of unknown origin                                    1/18 (5.6%)
   gout                                                       1/18 (5.6%)
   seizures (history of seizure disorder)                     1/18 (5.6%)
   sarcoid                                                    1/18 (5.6%)
   gastroparesis                                              1/18 (5.6%)
   left against medical advice                                1/18 (5.6%)
   unknown                                                    1/18 (5.6%)
  Issues relating to receipt of treatment at home (*n* = 3)   
   drug use                                                   2/18 (11.1%)
   *C. difficile* colitis                                     1/18 (5.6%)
  Study drug                                                  
   daptomycin                                                 9/50 (18.0%)
   vancomycin                                                 4/30 (13.3%)
   semi-synthetic penicillin                                  5/23 (21.7%)
  Final diagnosis                                             
   uBAC                                                       2/27 (7.4%)
   cBAC                                                       10/51 (19.6%)
   RIE                                                        6/19 (31.6%)
   LIE                                                        0/6
  Intravenous drug user                                       
   no                                                         11/77 (14.3%)
   yes                                                        7/26 (26.9%)

CoPAT, outpatient parenteral antimicrobial therapy in the community setting; uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis; LIE, left-sided infective endocarditis.

^a^One patient was readmitted twice for reasons relating to treatment at home.

^b^No. (%).

IVDU was associated with an increased risk of hospital readmission for CoPAT patients, with 7/26 (26.9%) IVDU patients requiring readmission, compared with 11/77 (14.3%) non-IVDU patients requiring readmission. The use of iv drugs during therapy was documented in two of the seven readmitted IVDU patients. Also of note was the fact that a higher proportion of patients with right-sided IE (6/19, 31.6%), though not statistically significant, required hospital readmission compared with those with other final diagnoses (Table [6](#DKP051TB6){ref-type="table"}). Five of the six readmitted patients with right-sided IE were iv drug users (four complicated right-sided IE and one uncomplicated right-sided IE).

Discussion {#s4}
==========

Numerous publications have described clinical experiences with OPAT in various countries, in some cases over extended periods of time, showing it to be generally safe, effective, convenient and economically beneficial when properly administered.^[@DKP051C8],[@DKP051C11],[@DKP051C14]--[@DKP051C18]^ These publications typically draw data from local or national OPAT registries or from the databases of hospitals or other facilities offering outpatient iv antimicrobial therapy services and that describe the experience of tens of thousands of patients. However, despite the voluminous data on OPAT, the availability of data from controlled clinical trials is meagre, especially among patients treated for MRSA infection,^[@DKP051C19],[@DKP051C20]^ and it is poorer still in patients with SAB/IE.

Limited published data on outpatient iv antimicrobial therapy for various kinds of bacterial infections (not limited to *S*. *aureus*) indicate a hospital readmission rate of ∼8% to 30%,^[@DKP051C21],[@DKP051C22]^ a range that includes the 17.5% rate observed in the present study. It should be noted that these data are based on a variety of different infections---including prosthetic infections, osteomyelitis, septic arthritis and soft tissue infections---that may be expected to have lower rates of readmission than SAB.

Of additional interest are the results from a recently published UK study by Matthews *et al.*,^[@DKP051C14]^ which compared 'self-administered' OPAT (i.e. parenteral antibiotic therapy administered by patients, relatives or caretakers) with OPAT administered by community-based healthcare workers. This study, which analysed data collected over 13 years and included 2059 patients, found no significant difference between the two approaches in either hospital readmissions (10.5% versus 12.6%, *P* = 0.3) or complications.^[@DKP051C14]^ It should be noted that 39% and 26.3%, respectively, of patients whose therapy was self-administered or given by healthcare workers were being treated for *S*. *aureus* infections.^[@DKP051C14]^

In 1992, it was estimated that ∼300 000 Americans are treated annually with outpatient iv antimicrobial therapy;^[@DKP051C23]^ it is likely that the number of courses of therapy has increased since then. The savings associated with outpatient treatment in such a large number of patients could be significant, since hospital stay represents ∼60% to 90% of the total cost of treating serious infections.^[@DKP051C24],[@DKP051C25]^ Data from the present study support findings from previous studies of decreased length of hospital stay, which has been shown to reduce costs and would also likely reduce the risk of nosocomial infection.^[@DKP051C16],[@DKP051C18]^ Detailed economic analysis of this study is ongoing.

Previous experience with OPAT suggests that success is most likely in patients with uncomplicated infections and in situations where appropriate agents and means of delivery are available.^[@DKP051C26],[@DKP051C27]^ While there is a certain variability in the requirements for managing IE with outpatient therapy, guidelines created by the American Heart Association and endorsed by the Infectious Diseases Society of America (IDSA) list the following minimal conditions for treatment in the home setting:^[@DKP051C27]^ reliable caretaker support and easy access to a hospital; regular visits by a home infusion nurse; and regular consultation (e.g. weekly) with a physician for assessment of clinical status. In the case of *S*. *aureus* IE, more stringent guidelines have been suggested. These include: hospitalization during the initial 2 week critical period (and possibly for a continuation phase of up to 2--4 weeks), patient education regarding potential complications as well as methods of contacting medical staff, proximity to the hospital, and biweekly office visits or home visits from the healthcare team.^[@DKP051C13]^

The optimal approach to outpatient treatment of SAB/IE for patients with a history of IVDU remains unclear. iv drug users typically respond well to treatment and have a similar, and possibly lower, mortality rate compared with other bacteraemia patients.^[@DKP051C28]--[@DKP051C30]^ The high cure rate among iv drug users with endocarditis has been partly attributed to the majority of infections involving the tricuspid valve, which responds particularly well to antimicrobial therapy as opposed to those involving the aortic or mitral valves.^[@DKP051C31]^ Among iv drug users, the rate of complications does not appear to be higher overall compared with other patients, although limited data suggest a higher rate of vascular events.^[@DKP051C28]^ The decision to discharge iv drug users to community settings is complicated by the potential for relapse of IVDU and suboptimal adherence to recommendations. These concerns may lead physicians to choose treatment settings with greater levels of supervision and structure. In this study, the rate of hospital readmission among iv drug users on CoPAT was nearly double that of CoPAT patients who were not iv drug users. It is worth noting that of the seven iv drug users readmitted to the hospital, two were found to have resumed use of iv drugs. Caution should be exercised in the selection and management of iv drug users who are candidates for CoPAT, as active drug use leads to safety and efficacy problems.

The current IDSA guidelines emphasize that when CoPAT therapy is considered, the antimicrobial agent selected should be effective against the causative pathogen, preferably dosed once daily, have a minimal adverse event profile, limited therapeutic drug monitoring and be stable in dosing formulations.^[@DKP051C32]^ The clinical trial upon which this analysis was based compared standard therapy (semi-synthetic penicillins or vancomycin with initial low-dose gentamicin) for SAB/IE with daptomycin, the first of a new class of cyclic lipopeptide antimicrobials.^[@DKP051C12]^ The standard treatment options may pose logistical challenges when used for CoPAT. Semi-synthetic penicillins are considered standard therapy for SAB/IE caused by MSSA but may be difficult to administer in the outpatient setting because of the need for multiple daily doses (up to six times per day), as well as tolerability issues such as rash and diarrhoea.^[@DKP051C8],[@DKP051C33],[@DKP051C34]^ Vancomycin is considered by many to be standard treatment for SAB/IE caused by MRSA, but it requires infusion over at least 1 h and therapeutic drug monitoring. In addition, a growing body of literature suggests inconsistent vancomycin efficacy because of changes in *S*. *aureus* susceptibility.^[@DKP051C35]--[@DKP051C38]^ Alternative agents such as daptomycin, which are conducive to use in the outpatient setting, are needed, particularly for MRSA infections.^[@DKP051C8],[@DKP051C31],[@DKP051C39]--[@DKP051C42]^ Daptomycin is an effective alternative to standard therapy,^[@DKP051C12],[@DKP051C42]^ and its dosing schedule (once every 24 h for patients with a CL~CR~ ≥30 mL/min or once every 48 h when the creatinine is \<30 mL/min) is convenient for CoPAT. After reconstitution and dilution in iv solution, daptomycin is stable under refrigeration for 48 h per the current FDA-approved package insert.^[@DKP051C43]^

Limitations {#s4a}
-----------

The comparison of clinical outcomes between patients treated in the CoPAT and IPAT settings must be understood in the context of the patients\' severity of illness. Candidates for outpatient antimicrobial therapy typically are stable patients at low risk of developing complications. The lower clinical success rate observed in the IPAT group in this study would be expected because of the greater severity of illness in these patients. One strength of this analysis is that it is based on data from a randomized, controlled clinical trial. However, the trial was not prospectively designed to assess outpatient versus inpatient care, and the retrospective nature of the current analysis may result in bias. In addition, as patients were followed only while receiving the study drug, treatment after study drug discontinuation was not captured.

It should be noted that outpatient antimicrobial therapy was provided at no cost as part of the trial, thereby potentially limiting the cost-related biases typically inherent in studies comparing inpatient with outpatient treatment. This aspect of the trial does not reflect real-life practice, where reimbursement for outpatient therapy varies depending on an individual\'s insurance coverage, and this may limit generalization of the study results. Furthermore, in analysing data only from US centres participating in the trial, the results draw on a smaller patient population than that of the original study, and may apply primarily in the USA.

Conclusions {#s4b}
-----------

The present study demonstrates that stable patients with SAB/IE can successfully complete iv antibacterial therapy in the outpatient setting. Proper monitoring of these patients is necessary, as changes in their conditions may necessitate an escalation of care. This study further demonstrates that daptomycin is an appropriate treatment option for patients with SAB/IE who are completing therapy in the outpatient setting. Additional research is warranted to define selection criteria for patients with SAB/IE who may be candidates for outpatient therapy.
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